Evidence map›Paper›PMID 32408488›Full record

ArticleBiomolecules2020

Novel Targets and Therapeutic Strategies for Promoting Organ Repair and Regeneration.

Shanmugam Muruganandan, Michael Wigerius

Abstract readEditorial
In one paragraph

Article in Biomolecules, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Shanmugam MuruganandanDepartment of Developmental Biology, Harvard School of Dental Medicine, Harvard University, 188 Longwood Avenue, Boston, MA 02115, USA.
Michael WigeriusDepartment of Pharmacology, Dalhousie University, 1348 Summer street, North tower 3rd floor, Halifax, NS B3H 4R2, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Strategies to create functional organs and tissues is of great interest for use in regenerative medicine in order to repair or replace the lost tissues due to injury, disease, as well as aging. Several new treatment options, including stem cell treatments and tissue-engineered substitutes for certain indications, have been approved by Food and Drug Administration (FDA) and are currently available. This special issue will cover new therapies and strategies that are currently being investigated under preclinical and clinical settings.

Indexed as

Regenerative MedicineTissue EngineeringAnimalsBioengineeringDisease Models, AnimalHumansMesenchymal Stem Cell TransplantationSwineTissue Scaffolds

Identifiers

PMID32408488
PMCPMC7277736

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.